VBI Vaccines updates on glioblastoma vax progress; Scripps team nets $1.6M for heroin addiction vaccine;

> Cambridge, MA-based VBI Vaccines ($VBIV) said data confirm the "desired integrity and quality" of its candidate glioblastoma vaccine; it has a pre-IND meeting with the FDA in the first half of 2016. Release

> A team at The Scripps Research Institute received $1.6 million through the Translational Avant-Garde Award program to work on a vaccine to combat heroin addiction. Report

> The Sabin Vaccine Institute, through its Product Development Partnership, teamed up with King Saud University to grow vaccine research capabilities in the Middle East. Report

> Baltimore, MD-based Vaccinogen signed on with Dublin City University to get its hands on the biotechnology analysis platform DiCast. Report

> Memphis, TN-based Hapten Sciences announced it's commencing trials of its poison ivy vaccine candidate. Release

Suggested Articles

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.

Pfizer posted positive top-line results for a trial of its 20-valent pneumococcal vaccine, potentially setting up a filing by the end of 2020.

Univercells's new CDMO, Exothera, is hoping to play a role in helping drugmakers scale up manufacturing for a possible COVID-19 vaccine.